RGD targeting of human ferritin iron oxide nanoparticles enhances in vivo MRI of vascular inflammation and angiogenesis in experimental carotid disease and abdominal aortic aneurysm

PurposeTo evaluate Arg-Gly-Asp (RGD)-conjugated human ferritin (HFn) iron oxide nanoparticles for in vivo magnetic resonance imaging (MRI) of vascular inflammation and angiogenesis in experimental carotid disease and abdominal aortic aneurysm (AAA). Materials and MethodsHFn was genetically engineered to express the RGD peptide and Fe3O4 nanoparticles were chemically synthesized inside the engineered HFn (RGD-HFn). Macrophage-rich left carotid lesions were induced by ligation in FVB mice made hyperlipidemic and diabetic (n=14), with the contralateral right carotid serving as control. Murine AAAs were created by continuous angiotensin II infusion in ApoE-deficient mice (n=12), while control mice underwent saline infusion (n=8). All mice were imaged before and after intravenous injection with either RGD-HFn-Fe3O4 or HFn-Fe3O4 using a gradient-echo sequence on a whole-body 3T clinical scanner, followed by histological analysis. The nanoparticle accumulation was assessed by the extent of T2*-induced carotid lumen reduction (% lumen loss) or aortic T2*-weighted signal intensity reduction (% SI [signal intensity] loss). ResultsRGD-HFn-Fe3O4 was taken up more than HFn-Fe3O4 in both the ligated left carotid arteries (% lumen loss; 699% vs. 367%, P=0.01) and AAAs (% SI loss; 476% vs. 20 +/- 5%, P=0.01). The AAA % SI loss correlated positively with AAA size (r=0.89, P < 0.001). Histology confirmed the greater accumulation and colocalization of RGD-HFn-Fe3O4 to both vascular macrophages and endothelial cells. ConclusionRGD-HFn-Fe3O4 enhances in vivo MRI by targeting both vascular inflammation and angiogenesis, and provides a promising translatable MRI approach to detect high-risk atherosclerotic and aneurysmal vascular diseases.